Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06488365 · ClinicalTrials.gov registry record · NA

In Vivo Liquid Biopsy of Melanoma (Cytophone)

A NA study of Melanoma and Metastatic Melanoma, sponsored by Cytoastra.

Recruiting
Registry status
NA
Development phase
180
Enrollment target
1
Study location

NCT06488365: Recruiting NA study of Melanoma and Metastatic Melanoma, sponsored by Cytoastra.

NCT06488365 is a NA study of Melanoma and Metastatic Melanoma that is actively recruiting participants, run by Cytoastra. The registered enrollment target is 180 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06488365, a NA study of Melanoma and Metastatic Melanoma, is actively recruiting participants, sponsored by Cytoastra.

RECRUITING
Registry status
NA
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a unique capability to find rare melanoma cells in the blood by an assessment of 100-500 times greater amounts of blood volume than routine blood tests. The important benefit of the Cytophone diagnosis is that the test does not require injection or any skin incision (i.e., non-invasiveness). The goal of this clinical trial is to demonstrate evidence of the capability of the Cytophone test to indicate a risk of metastasis and define CTC counts that correlate with melanoma recurrence, progression of metastatic disease, and therapy efficacy. The investigators believe that clinical trials will provide evidence that the Cytophone can diagnose risk of melanoma metastasis and recurrence earlier than existing methods.

Primary Outcome

Link CTC counts with early melanoma progression and recurrence efficacy

Interventions

  • DEVICE Cytophone

Study Locations (1)

Wisconsin

  • SSM Health Dean Medical Group Specialty Services - Madison

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2025-02-11
Est. Completion 2026-03-31
Phase NA
Cytoastra

1 total trials

What NCT06488365 shows while recruiting

NCT06488365 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (75% lower).

The record links to 4 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Cytophone is the first listed.

NCT06488365 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06488365 about?

NCT06488365 is a clinical study titled "In Vivo Liquid Biopsy of Melanoma (Cytophone)". The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a unique capability to find rare melanoma cells in the blood by an assessment of 100-500 times greater amounts of blood volume t...

What is the current status of trial NCT06488365?

This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2025-02-11. Estimated completion is 2026-03-31.

What conditions does trial NCT06488365 study?

This clinical trial studies the following conditions: Melanoma, Metastatic Melanoma, Diagnosis, Circulating Tumor Cells.

What interventions are being tested in trial NCT06488365?

The interventions under investigation include: Cytophone (DEVICE).

Who is sponsoring clinical trial NCT06488365?

This trial is sponsored by Cytoastra, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06488365 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06488365's enrollment target sits among peer trials

180 73rd of 266 higher than 193 of 266 other Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06488365, the US trial registry maintained by the National Library of Medicine. NCT06488365 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.